ERBB2 and breast cancer: Due to the decreased cost of gBRCA testing and the promising efficacy of olaparib therapy to improve survival in patients with breast cancer and BRCA1/2 PVs, it is essential to examine whether gBRCA testing is appropriate for all patients with TNBC and HR-positive HER2-negative breast tumours [9, 10, 18].